Formulation and Evaluation of Fluconazole Gel for Topical Application
Objective: The development of topical gel formulation is needed because it offers an interesting alternative for oral route to achieving systemic and local effect of drug. Topical gel is having important advantages like avoid GI irritation, avoid first pass metabolism and increase the bioavailability of the drug. Fluconazole is a synthetic triazole antifungal drug used in the treatment and prevention of superficial and systemic fungal infection. Adverse effects reported with fluconazole most commonly affect the gastrointestinal tract and include abdominal pain, diarrhoea, flatulence, nausea and vomiting, and taste disturbance after oral administration. In order to bypass these disadvantages, the gel formulations have been proposed as topical application.
Method: Topical gel was prepared using combination of Carbopol and guar gum. Evaluation of the topical gel of fluconazole was carried out for physical appearance, pH, Spreadability, Extrudability, Rheological studies, Drug content, antifungal activity, in vitro release, Ex- vivo permeation study and skin irritation study.
Result: The varying concentrations of two polymers were found to affect the gel parameters like drug release, Spreadability and its viscosity. The accelerated stability studies were performed according to ICH guidelines for 3 months and the results were found to be stable in varying temperature.
2. Abdel-Mottaleb MMA, Mortada ND, Elshamy AA, Awad GAS. Preparatio and evaluation of fluconazole gels. Egyptian Journal of Biomedical Sciences.(2007);23:266-286.
3. Banker GS, Rhode CT. Modern Pharmaceutics. ed. New York: Marcel Dekker; 2002:294
4. Aulton ME. The Science of Dosage Form Design Pharmaceutics. 2nd ed. London: Churchill Livingstone; 2002, 500-533.
5. Sudhir Bharadwaj, Gupta GD and Sharma VK. Topical gel a noval approach for drug delivery, Journal of Chemical, Biological and Physical sciences, (2012). 2(2):856-867.
6. Sankar VR, Reddy YD, Reddy GH. Formulation of Nimesulide Microemulsion based Hydrogel for Topical Delivery: In-vitro and Ex-vivo Characterization. Inventi Impact: Novel drug delivery systems. (2013); 3:225-230
7. Mekkawy A, Fathy M, El-Shanawany S. Formulation and In vitro Evaluation of Fluconazole Topical Gels. British Journal of Pharmaceutical Research.(2013); 3(3):293-313.
8. Basha BN, Prakasam K, Goli D. Formulation and evaluation of Gel containing Fluconazole-Antifungal Agent. International Journal of Drug Development and Research. (2011); 3 (4):109-128
9. Bhanja S, Kumar P, Sudhakar M, Das AK. Formulation and Evaluation of Diclofenac Transdermal Gel. Journal of Advanced Pharmacy Education & Research. (2013); 3(3):248-259.
10. Marabathuni J, Rajamanickam D, Srinivasan B, Veerabhadraiah BB, Varadharajan M. Development and Evaluation of Ketoprofen Microsponge Loaded Hydrogel Delivery System. Inventi Impact: Pharm Tech. (2012); 2:89-93.
11. Fasale PD,Wadkar KA, Mohite SK. Development and evaluation of topical gel containing ketorolac tromethamine. International Journal of Universal Pharmacy and Bio sciences. (2013); 2(4): 258-266
12. Chandira RM, PasupathiPA, Bhowmik D, Jayakar CB, Tripathi KK , Sampath Kumar KP. Design, Development and Formulation of Antiacne Dermatological Gel. Journal of Chemical and Pharmaceutical Research. (2010); 2(1):401-414.
13. Khullar R , Kumar D, Seth N, Saini S. Formulation and evaluation of mefenamic acid emulgel for topical delivery. Saudi Pharmaceutical Journal. (2012); 20:63–67
14. Lalit SK, Panwar AS, DarwhekarG, Jain DK. Formulation and Evaluation of Fluconazole Amphiphologel. Scholors Research Library. Der Pharmacia Letter. (2011);3 (5) :125-131
15. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. ActaPoloniaePharmaceutica Drug Research. (2010); 67(3):217-223
16. Lackman L, Leiberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Varghese Publishing House; 1991, 534-547.
17. ICH Harmonized Tripartite Guideline, International Conference on Harmonization. Stability testing of new drug substances and products Q1A (R2) and Evaluation for stability data Q1E. Current step version, 6 February 2003.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).